Inhibrx, Inc. (INBX) Bundle
An Overview of Inhibrx, Inc. (INBX)
General Summary of Inhibrx, Inc. (INBX)
Inhibrx, Inc. is a biotechnology company headquartered in San Diego, California, focused on developing novel antibody therapeutics. The company was founded in 2010 and specializes in oncology and immunology treatments.
Key Company Products and Services
- INBRX-106: A clinical-stage antibody targeting CD39
- INBRX-105: A therapeutic candidate for solid tumors
- INBRX-130: An immunotherapy development program
Financial Performance in Latest Reporting Period
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $14.2 million |
| Net Loss | ($76.3 million) |
| Cash and Cash Equivalents | $126.7 million |
| Research and Development Expenses | $62.4 million |
Industry Leadership Highlights
Inhibrx demonstrates leadership through:
- Advanced clinical-stage antibody pipeline
- Innovative immunotherapy approaches
- Strategic collaborations with major pharmaceutical companies
Market Position
| Market Metric | 2024 Status |
|---|---|
| Market Capitalization | $387.5 million |
| Stock Price (INBX) | $8.45 per share |
| Clinical Trial Progress | 3 ongoing Phase 1/2 trials |
Mission Statement of Inhibrx, Inc. (INBX)
Mission Statement of Inhibrx, Inc. (INBX)
Inhibrx, Inc. focuses on developing innovative immunotherapies targeting serious diseases, with a specific emphasis on oncology and rare disorders.
Core Mission Components
| Research Focus | Precision immunotherapy development |
| Target Therapeutic Areas | Oncology, rare diseases |
| R&D Investment | $48.3 million in 2023 |
Key Strategic Objectives
- Advanced therapeutic pipeline targeting TNBC and other cancers
- Development of novel bispecific antibody platforms
- Clinical-stage immunotherapy research
Research Pipeline Metrics
| Total Active Clinical Programs | 4 programs |
| Lead Product INBRX-106 Stage | Phase 1/2 clinical trials |
| Patent Portfolio | 37 issued patents |
Financial Performance Indicators
Cash and cash equivalents as of December 31, 2023: $218.4 million
Scientific Innovation Focus
- Proprietary TITAN™ antibody platform
- Engineered bispecific antibody technologies
- Targeted immunotherapy mechanisms
Vision Statement of Inhibrx, Inc. (INBX)
Vision Statement of Inhibrx, Inc. (INBX)
Innovative Biotechnology DevelopmentInhibrx, Inc. focuses on developing novel immunotherapies targeting complex diseases. As of Q4 2023, the company's research pipeline concentrated on advancing tetravalent antibody platforms and novel therapeutic approaches.
| Research Focus Area | Current Status | Development Stage |
|---|---|---|
| Oncology Immunotherapies | Active Clinical Trials | Phase 1/2 |
| Rare Disease Treatments | Preclinical Development | Investigational |
- Develop precision immunotherapeutic platforms
- Target challenging disease mechanisms
- Leverage tetravalent antibody technology
Market capitalization as of January 2024: $246.7 million. Research and development expenditure in 2023: $47.3 million.
Key Pipeline Innovations| Program | Therapeutic Area | Current Phase |
|---|---|---|
| INBX-A | Solid Tumors | Phase 2 |
| INBX-B | Rare Genetic Disorders | Preclinical |
Intellectual property portfolio: 38 issued patents as of December 2023.
Core Values of Inhibrx, Inc. (INBX)
Innovative Scientific Research and Development
Inhibrx, Inc. demonstrates commitment to innovative scientific research and development through targeted biopharmaceutical initiatives.
| R&D Metric | 2024 Value |
|---|---|
| Total R&D Expenses | $48.3 million |
| Active Clinical Trials | 7 ongoing programs |
| Research Personnel | 52 specialized scientists |
Patient-Centric Approach
Inhibrx prioritizes patient outcomes through focused therapeutic development strategies.
- Oncology therapeutic pipeline targeting rare cancer indications
- Precision medicine development approach
- Clinical trial design emphasizing patient experience
Collaborative Scientific Integrity
Commitment to transparent and ethical scientific research practices.
| Collaboration Metric | 2024 Status |
|---|---|
| Academic Research Partnerships | 4 active collaborations |
| Published Research Papers | 12 peer-reviewed publications |
Sustainable Innovation
Focused on developing transformative therapeutic technologies.
- Advanced antibody drug conjugate platform
- TRIDENT™ bispecific antibody technology
- Next-generation immunotherapy research
Inhibrx, Inc. (INBX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.